SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Questcor Pharmaceuticals, Inc. - QCOR

NEW YORK, April 7, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Questcor Pharmaceuticals, Inc. ("Questcor" or the "Company") (NASDAQ: QCOR) (ISIN: US74835Y1010) (CUSIP: 74835Y101) concerning the proposed acquisition of Questcor by Mallinckrodt Plc.        

The investigation concerns whether the Questcor directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value.  Under the terms of the transaction, Questcor shareholders will receive $86.08 in a combination of cash and stock for each share of Questcor common stock owned.  However, the Price to EBITDA and Revenue multiples are below the averages of comparable transactions.  Additionally, at least one analyst has set a target price of $99.00 per share for Questcor common stock.

Questcor shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at [email protected] or 212-661-1100 or 888-476-6529, ext. 237.

Pomerantz LLP, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz LLP pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz LLP continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.

CONTACT:
Robert Willoughby
Pomerantz LLP
212-661-1100 ext. 237
[email protected]

SOURCE Pomerantz LLP